Viral load and CD4+ cell count as risk factors for prolonged QT interval in HIV-infected subjects: A cohort-nested case-control study in an outpatient population

Cardiology

Volumn 117, Issue 2, 2010, Pages 105-111

  Qaqa, Ashraf Y ^a   Shaaban, Hamid ^a   Debari, Vincent A ^a   Phung, Suzan ^a   Slim, Jihad ^a   Costeas, Constantinos A ^a   Perez, George ^a   Shamoon, Fayez E ^a,b  

^a SETON HALL UNIVERSITY   (United States)

^b ST MICHAEL S MEDICAL CENTER   (United States)

Author keywords

CD4+; HIV; QTc interval; Viral load

Indexed keywords

ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; VIRUS LOAD;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; OUTPATIENTS; RISK FACTORS; ROC CURVE; VIRAL LOAD;

EID: 77957996686     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320216     Document Type: Article

References (22)

1. Velasquez EM, Glancy DL: Cardiovascular disease in patients infected with the human immunodeficiency virus. J La State Med Soc 2003;155:314-324.
2. Sani MU, Okeahialam BN: QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005;97:1657-1661.
3. Dumaine R, Antzelevitch C: Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002;17:36-42. (Pubitemid 34073162)
4. Baker JR, Best AM, Pade PA, McCance-Katz EF: Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006;40:392-396.
5. Singh M, Arora R, Jawad E: HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. Am J Ther 2009, E-pub ahead of print.
6. Charbit B, Rosier A, Bollens D, Boccara F, Boelle PY, Koubaa A, et al: Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients. Br J Clin Pharmacol 2009;67:76-82.
7. Anson BD, Weaver JG, Ackerman MJ, et al: Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365:682-686.
8. Sani MU: Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr 2008;120:77-87.
9. Fiala M, Popik W, Qiao JH, Lossinsky AS, Alce T, Tran K, et al: HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovasc Toxicol 2004;4:97-107.
10. Villa A, Foresti V, Confaloneri F: Autonomic neuropathy and prolongation of the QT interval in human immunodeficiency virus infection. Clin Auton Res 1995;5:48-52.
11. Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ: Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997;20:2810-2816.
12. Nordin C, Kohli A, Beca S, Zaharia V, Grant T, Leider J, et al: Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 2006;39:199-205.
13. Sadanaga T, Sadanaga F, Yao H, Fujishima M: Heart rate dependent modification of the QTc cut-off values can improve accurate evaluation of QT prolongation. Am J Cardiol 2004;93:772-775.
14. El-Sherif N, Turitto G: Torsade de pointes. Curr Opin Cardiol 2003;18:6-13.
15. Schouten EG, Dekker JM, Meppelink P, et al: QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991;84:1516-1523.
16. Gowda RM, Khan IA, Wilbur SL, et al: Torsade de pointes: the clinical considerations. Int J Cardiol 2004;96:1-6.
17. Zareba W: Drug induced QT prolongation. Cardiol J 2007;14:523-533.
18. Moss AJ: Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993;72:23B-25B.
19. Reinsch N, Buhr C, Krings P, Kaelsch H, Neuhaus K, Wieneke H, et al: Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIVHEART study. HIV Clin Trial 2009;10:261-268.
20. Hrovatin E, Zardo F, Brieda M, Dametto E, Piazza R, Antonini-Canterin F, et al: Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450 (in Italian). Ital Heart J Suppl 2004;5:735-740.
21. Martell BA, Arnsten JH, Krantz M, Gourevitch MN: The impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005;95:915-918.
22. Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, et al: Blockade of HERG channels by HIV protease inhibitors. Lancet 2005;365:682-686.